Summaries drawn from peer-reviewed literature. All answers cite published sources. Compiled by the Pokai Research team — last reviewed June 2026.
Research peptides are short chains of amino acids (typically 2–50 residues) synthesized in laboratories for scientific investigation. They are used in preclinical studies of metabolic, regenerative, and neuroendocrine signaling pathways, and are sold strictly for laboratory research use — not for human consumption.
Nat Rev Drug Discov (2017) · PubMedPeptide purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry. These techniques quantify the proportion of the target compound relative to impurities such as deletion sequences, oxidized variants, or solvent residues. Research applications require high purity — commonly ≥98% — to ensure that observed biological effects can be attributed to the intended molecule rather than contaminants. Independent third-party certificates of analysis (COAs) provide an objective record of purity at the time of synthesis.
J Pept Sci (2019) · PubMedA Certificate of Analysis (COA) is a document from an accredited analytical laboratory confirming a compound's identity, purity, and potency. For research peptides it typically includes HPLC chromatograms and mass spectrometry data. Independent third-party COAs are the gold standard for verifying compound quality.
USP General Chapter ⟨1058⟩ · PubMedThe distinction is primarily structural and functional. Peptides are short amino acid chains (generally fewer than 50 residues) that typically lack a fixed tertiary structure, while proteins are longer chains that fold into defined 3-D conformations essential to their function. Peptides tend to act as signaling molecules — hormones, neuropeptides, or growth factors — binding receptors to modulate downstream cascades. Their smaller size also influences route of administration, half-life, and synthetic accessibility relative to full-length proteins.
Biochemistry (Stryer, 9th ed.) · PubMedLyophilized (freeze-dried) peptides are the most stable form for long-term storage. In powder form, most synthetic peptides remain stable for 12–24 months when stored at −20 °C in a desiccated, light-protected environment. Reconstitution with sterile bacteriostatic water — which contains 0.9% benzyl alcohol as a preservative — allows repeated use from a single vial over several weeks when refrigerated at 2–8 °C. Peptides containing cysteine, methionine, or tryptophan residues may require additional antioxidant precautions and have shorter reconstituted half-lives.
Eur J Pharm Biopharm (2015) · PubMedRetatrutide (LY3437943) is a tri-agonist research peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data published in NEJM (2023) reported roughly 17% mean body-weight reduction over 24 weeks at the highest dose studied, among the largest effects reported in obesity research.
N Engl J Med (2023) · PubMedAOD-9604 is a synthetic analog of the C-terminal fragment (residues 177–191) of human growth hormone, modified with a tyrosine at the N-terminus. Unlike full-length hGH, AOD-9604 does not bind the growth hormone receptor or stimulate IGF-1 production, meaning it does not produce the anabolic, hyperglycemic, or epiphyseal effects of exogenous GH. Research has focused on its interaction with beta-adrenergic receptors in adipose tissue as a potential mechanism for selective lipolysis. Animal studies have demonstrated fat-mobilizing activity without the metabolic side effects associated with intact GH.
Mol Cell Endocrinol (2001) · PubMedTesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) stabilized by the addition of a trans-3-hexenoic acid group at the N-terminus, which confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation. It stimulates the pituitary to release endogenous growth hormone in a pulsatile, physiological pattern, which in turn elevates IGF-1. The resulting GH/IGF-1 axis activation increases lipolysis preferentially in visceral fat depots — a mechanism demonstrated in randomized controlled trials of HIV-associated lipodystrophy, where significant reductions in trunk fat were observed at 26–52 weeks.
JAMA (2010) · PubMedGlucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by K-cells of the duodenum in response to nutrient ingestion. Beyond its classical role in potentiating glucose-stimulated insulin secretion, GIP receptors are expressed in adipose tissue, where GIP promotes lipid storage under fed conditions. Paradoxically, antagonism of the GIP receptor in rodent models reduces obesity, while GIP receptor agonism in the context of combined GLP-1 co-agonism (as in tirzepatide) enhances weight loss beyond GLP-1 alone. The mechanistic explanation for this apparent duality remains an active area of metabolic research.
Cell Metab (2022) · PubMedBPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. Preclinical research has studied its effects on angiogenesis, nitric oxide signaling, and tissue repair, with rodent studies reporting accelerated tendon, muscle, and gastrointestinal healing. Human clinical data remain limited.
Curr Pharm Des (2018) · PubMedTB-500 is a synthetic version of Thymosin Beta-4, one of the most abundant peptides in mammalian cells. It regulates actin polymerization, which drives cell migration and wound healing. Research shows it promotes keratinocyte and endothelial cell migration, stimulates angiogenesis, and reduces inflammation in preclinical models.
Ann N Y Acad Sci (2012) · PubMedBPC-157 and Thymosin Beta-4 (TB-500) are hypothesized to have complementary mechanisms in preclinical tissue-repair models. BPC-157 primarily exerts effects via NO-system modulation and VEGF-mediated angiogenesis, while Tβ4 operates through actin sequestration, cell migration promotion, and anti-inflammatory NF-κB suppression. Animal studies evaluating the combination suggest additive effects on tendon healing and wound closure that exceed either peptide alone. This synergy hypothesis has driven interest in combination formulations for preclinical musculoskeletal research, though controlled human data for the combination remain absent from the published literature.
J Orthop Res (2015) · PubMedSeveral preclinical studies have examined BPC-157's interaction with the nitric oxide system and prostaglandin pathways as potential anti-inflammatory mechanisms. In animal models of inflammatory bowel disease, colitis, and surgically induced lesions, BPC-157 demonstrated suppression of pro-inflammatory cytokines including TNF-α and IL-6. Some research implicates modulation of the cyclooxygenase (COX) pathway and stabilization of gastrointestinal mucosal integrity. The peptide's stability in gastric acid makes oral administration theoretically feasible, a property uncommon among larger peptides, though this has primarily been studied in rodent gastric lesion models.
J Physiol Pharmacol (2009) · PubMedMOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome rather than the nuclear genome. It activates AMPK, a central energy-sensing enzyme. Mouse studies report improved insulin sensitivity, reduced diet-induced obesity, and extended median lifespan, making MOTS-c an active subject of longevity research.
Cell Metab (2015) · PubMedSS-31 (Szeto-Schiller peptide 31; elamipretide) is a tetrapeptide with the sequence D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2 that selectively partitions into the inner mitochondrial membrane due to its alternating cationic and aromatic residues. Research indicates it binds cardiolipin — a lipid essential for cristae structure and the organization of respiratory chain supercomplexes — thereby reducing electron leak, superoxide generation, and cytochrome c release. Animal models of heart failure, ischemia-reperfusion injury, and age-related mitochondrial dysfunction have demonstrated improvements in ATP production and reductions in oxidative stress with SS-31 treatment.
J Am Heart Assoc (2016) · PubMedThe mitochondrial theory of aging posits that cumulative damage to mitochondrial DNA, membranes, and respiratory chain complexes reduces ATP production efficiency and increases reactive oxygen species (ROS) generation over time. This creates a positive feedback loop: ROS damage mitochondrial components further, impairing energy production and accelerating cellular senescence. Research in model organisms has demonstrated that interventions restoring mitochondrial biogenesis (via PGC-1α activation), reducing electron leak, or enhancing mitophagy can extend healthy lifespan. Peptides targeting these mitochondrial pathways — including MOTS-c and SS-31 — are of active research interest in the context of aging biology.
Cell (2013) · PubMedAMP-activated protein kinase (AMPK) is a heterotrimeric enzyme that acts as a cellular fuel gauge, activated when the AMP:ATP ratio rises (indicating energy deficit). Upon activation, AMPK inhibits anabolic processes (fatty acid synthesis, gluconeogenesis, protein synthesis) while stimulating catabolic pathways (fatty acid oxidation, autophagy, mitochondrial biogenesis). Pharmacological AMPK activators — including metformin and AICAR — extend lifespan in multiple model organisms. MOTS-c is among a small number of endogenous peptides that activate AMPK through a distinct retrograde mitochondrial signaling mechanism, placing it at the intersection of energy sensing and longevity pathways.
Nat Rev Mol Cell Biol (2011) · PubMedCJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) stabilized by DAC (drug affinity complex) technology, which significantly extends its plasma half-life by forming a covalent bond with albumin. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic — that stimulates pituitary GH release through a separate receptor pathway. Combining GHRH analog and GHSR agonist targets both primary regulatory inputs to pituitary somatotrophs, producing synergistic GH pulses in preclinical studies that are larger than either peptide alone while maintaining the physiological pulsatility that distinguishes this approach from continuous exogenous GH administration.
J Clin Endocrinol Metab (2006) · PubMedExogenous recombinant human growth hormone (rhGH) delivers a sustained, non-pulsatile elevation of circulating GH that bypasses normal hypothalamic-pituitary regulation. In contrast, GHRH analogs stimulate the pituitary to secrete its own GH in response to the hypothalamic signal, preserving pulsatility (high nocturnal pulses, lower daytime levels) and maintaining negative feedback through somatostatin. This physiological pattern is thought to reduce risks associated with continuous GH excess, including insulin resistance and IGF-1 overshoot. The relative benefit of GHRH-stimulated GH versus exogenous GH is an active area of endocrinological research.
Endocr Rev (2018) · PubMedInsulin-like growth factor 1 (IGF-1) is produced primarily in the liver in response to GH stimulation and mediates many of GH's downstream anabolic effects, including protein synthesis, cell proliferation, and bone mineral density maintenance. Serum IGF-1 levels serve as the primary clinical biomarker for GH axis activity because, unlike GH itself which is secreted in short pulses, IGF-1 has a longer plasma half-life and provides an integrated measure of GH secretion over hours to days. Research examining GHRH analogs like CJC-1295 and tesamorelin consistently uses IGF-1 as a primary pharmacodynamic endpoint in addition to direct GH pulse analysis.
Growth Horm IGF Res (2012) · PubMedThe somatotropic axis undergoes progressive decline with aging — a process termed somatopause. After peak GH secretion in late adolescence, mean 24-hour GH levels decline approximately 14% per decade, with corresponding reductions in IGF-1 and downstream anabolic signaling. This age-related decline correlates with increased visceral adiposity, decreased lean mass, reduced bone density, and impaired sleep architecture. Research has examined whether restoring youthful GH pulsatility through GHRH analogs or GH secretagogues could attenuate these changes, though the benefit-risk profile — particularly with respect to insulin resistance and potential neoplastic risk — remains under investigation.
J Endocrinol (2013) · PubMedTesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for its ability to stimulate pulsatile growth hormone secretion. Randomized controlled trials have documented significant reductions in visceral adipose tissue, making it one of the most clinically characterized GHRH analogs in published research.
JAMA (2010) · PubMedBacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits bacterial growth, allowing a reconstituted solution to be drawn from the same vial multiple times over several weeks in laboratory settings. It is the standard reconstitution vehicle for lyophilized research peptides.
USP Monograph — Bacteriostatic Water for Injection · PubMedSterile water contains no preservative and is intended for single use — once opened, it cannot prevent bacterial growth. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacteria and allows multiple withdrawals from one vial over several weeks. For multi-use peptide reconstitution in research, bacteriostatic water is standard.
Eur J Pharm Biopharm (2015) · PubMedBenzyl alcohol at 0.9% concentration acts as a bacteriostatic preservative — it stops bacteria from multiplying without needing refrigeration-grade sterility for every access. This allows researchers to draw from one reconstituted vial multiple times over a protocol while maintaining solution integrity.
Pharm Dev Technol (2011) · PubMedMost lyophilized peptides reconstituted in bacteriostatic water remain stable for roughly 3–4 weeks when refrigerated at 2–8 °C and protected from light. Stability varies by sequence — peptides containing cysteine, methionine, or tryptophan residues degrade faster and may require shorter usage windows in research protocols.
Eur J Pharm Biopharm (2015) · PubMed